Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody
OAKLAND, Calif. and NANJING, China, Nov. 7, 2024 /PRNewswire/ — Aditum Bio and Leads Biolabs today announced the formation of Oblenio Bio, which is being formed in conjunction with an exclusive option and license agreement to develop LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody for autoimmune diseases. Aditum Bio will fund Oblenio Bio and the parties will collaborate to rapidly bring LBL-051 into clinical studies.
Recent clinical data from CD19 and BCMA targeted therapies have demonstrated compelling efficacy in difficult-to-treat autoimmune diseases. Despite these promising results, there is a continued unmet need for increased efficacy and durability. By targeting both CD19 and BCMA, LBL-051 has the potential to deliver stronger and more durable responses by depleting a broader range of pathological B-cell populations across a wide spectrum of antibody-mediated autoimmune diseases.
LBL-051 is a novel tri-specific T-cell engager developed using the LeadsBody™ Platform. Each target binding domain CD19, BCMA, and CD3- has been engineered with the intent of enhancing safety while optimizing efficacy by finely tuning the relative potency of each domain.
Under the terms of the agreement, Leads Biolabs will grant Oblenio an exclusive option to develop, manufacture, and commercialize LBL-051 worldwide. Leads Biolabs is eligible to receive up to $35 million in upfront and near-term payments, $579 million in development, regulatory, and commercialization milestone payments, as well as royalties on sales. Additionally, Leads Biolabs is entitled to receive an equity stake in Oblenio Bio.
"By targeting both CD19 and BCMA in autoimmune disorders, LBL-051 has the potential to achieve a complete immune reset and superior efficacy and durability, compared to single targeting of either CD19 or BCMA alone", said Joe Jimenez, Co-Founder and Managing Director of Aditum Bio. Dr. Xiaoqiang Kang, Founder, Chairman and CEO of Leads Biolabs added, "LBL-051 offers a differentiated approach to treating certain autoimmune conditions and has the potential to be a Pipeline in a Product. We are pleased to establish this partnership with the high caliber team at Aditum to bring this innovative therapy to patients around the world".
Oblenio Bio is the thirteenth company launched by Aditum Bio, whose mission is to give large patient populations access to important medicines. To speed these drugs to market, Aditum Bio fosters an incubator model, focusing on the translational phase of drug development. The "spin out" model enables a nimble, start-up platform with a dedicated team of managers supported by Aditum’s in-house team of development professionals.
About Aditum Bio
Aditum Bio is a biotech venture firm committed to improving health by accelerating drug development in disease areas with high unmet need where medical innovation can have a significant impact. Aditum Bio in-licenses promising drug candidates and spins out individual companies dedicated to bringing each candidate through early clinical trials. For more information, please visit www.aditumbio.com.
About Leads Biolabs
Founded in 2014, Nanjing Leads Biolabs Co., Ltd. is a clinical-stage biotechnology company based in Nanjing, China, with operations extending to the U.S. Our focus is to discover and develop innovative therapies that address significant unmet medical needs in oncology, autoimmune diseases, metabolic disorders, and other serious conditions. Our robust R&D pipeline includes over twenty novel candidates across various modalities, including monoclonal antibodies, multi-specific antibodies, T cell engagers, and antibody-drug conjugates (ADCs). For more information, please visit https://en.leadsbiolabs.com/
Media
For inquiries to Aditum Bio, please contact:
Susie Phillips
Aditum Bio (510) 227-2096
[email protected]
For inquiries to Leads Biolabs, please contact:
Jordan Zhu
Leads Biolabs (747) 888-7396
[email protected]
The information provided in this article was created by Cision PR Newswire, our news partner. The author's opinions and the content shared on this page are their own and may not necessarily represent the perspectives of Siam News Network.